Blocking integrin β1 on monocytic myeloid-derived suppressor cells reduces TAMs, while dipeptidyl peptidase-4 (DPP-4) inhibition also diminished macrophage abundance, suggesting these molecules as potential immunotherapy targets in GBM. Here, DPP4 is linked to glioblastoma.